Drug Profile


Alternative Names: BCI-024/BCI-049; BCI-952

Latest Information Update: 01 Sep 2015

Price : $50

At a glance

  • Originator BrainCells
  • Class Antidepressants
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 25 Jun 2012 Buspirone/melatonin is available for licensing as of 25 Jun 2012. http://www.braincellsinc.com
  • 31 May 2008 Phase-II clinical trials in Major depressive disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top